FDA Brief

Warning letters Drugs

FDA warning letter to

Advanced Cosmetic Research Laboratories Inc.

High riskIssued Sep 26, 2022Posted Oct 25, 2022Division of Pharmaceutical Quality Operations IV

FDA cited Advanced Cosmetic Research Laboratories for manufacturing-quality violations at its Chatsworth drug plant and an unapproved 5% lidocaine cream.

What happened

FDA inspected the Chatsworth drug manufacturing facility from April 21 to 27, 2022, and found CGMP (current good manufacturing practice, the rules for drug manufacturing) violations: rusty or dirty pipes above partially open mixing tanks, falling ceiling panels, and bug zappers near filling lines. FDA also found the quality unit released a batch before filling was finished, did not investigate out-of-specification results, and did not record or investigate complaints. Separately, FDA said the 5% lidocaine cream is an unapproved new drug because 5% lidocaine is above the 0.5–4% allowed for over-the-counter external analgesics, and it is misbranded.

What FDA found

  1. The firm did not keep its buildings in a good state of repair, with rusty or dirty pipes above open mixing tanks, falling ceiling panels, and bug zappers near filling lines.

    21 CFR 211.58
  2. The quality control unit did not properly oversee production and release, including signing off a batch report before the batch was filled, not investigating out-of-specification results, and not recording or investigating complaints.

    21 CFR 211.22(a) and (d)
  3. The firm marketed 5% lidocaine cream as an unapproved new drug because 5% lidocaine exceeds the 0.5–4% allowed for over-the-counter external analgesics and FDA is not aware of studies supporting it as generally recognized as safe and effective.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  4. The 5% lidocaine cream is misbranded because it is a nonprescription drug subject to section 505G but does not meet that section’s requirements and has no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days, including CAPA plans, photographic evidence of repairs, quality-unit remediation, and assessments of investigations, documentation, and data integrity. If it cannot finish within 15 working days, it must explain the delay and give a completion schedule.

Who should pay attention

  • brands and retailers selling OTC topical drugs made by this contract manufacturer
  • consumers using 5% lidocaine cream
  • OTC drug companies relying on quality-unit release and complaint systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk